LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Innoviva Inc

Fermé

SecteurSoins de santé

22.86 -2.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

22.83

Max

22.99

Chiffres clés

By Trading Economics

Revenu

26M

90M

Ventes

7.5M

108M

P/E

Moyenne du Secteur

13.374

108.767

Marge bénéficiaire

83.403

Employés

127

EBITDA

25M

108M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+61.15% upside

Dividendes

By Dow Jones

Prochains Résultats

3 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

519M

1.7B

Ouverture précédente

25.38

Clôture précédente

22.86

Sentiment de l'Actualité

By Acuity

45%

55%

121 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 févr. 2026, 23:53 UTC

Actions en Tendance

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 févr. 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 févr. 2026, 21:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 15:20 UTC

Résultats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 févr. 2026, 14:43 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 14:38 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 févr. 2026, 13:47 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 13:44 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 févr. 2026, 13:14 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 févr. 2026, 02:32 UTC

Résultats
Acquisitions, Fusions, Rachats

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 févr. 2026, 02:00 UTC

Acquisitions, Fusions, Rachats

Six Months, 9 Offers and $81 Billion. How -2-

28 févr. 2026, 00:01 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 févr. 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 févr. 2026, 23:33 UTC

Acquisitions, Fusions, Rachats

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 févr. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

27 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 févr. 2026, 21:30 UTC

Résultats

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 févr. 2026, 21:30 UTC

Market Talk
Acquisitions, Fusions, Rachats

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 févr. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 févr. 2026, 21:17 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 févr. 2026, 21:10 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 févr. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 févr. 2026, 21:00 UTC

Résultats

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 févr. 2026, 20:31 UTC

Acquisitions, Fusions, Rachats

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 févr. 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 févr. 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 févr. 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 févr. 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 févr. 2026, 19:39 UTC

Résultats

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

61.15% hausse

Prévisions sur 12 Mois

Moyen 37 USD  61.15%

Haut 46 USD

Bas 32 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

121 / 352Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat